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Lipid bilayerThe functional effects of a drug ligandmay beduenot only to an interactionwith itsmembrane protein target, but
also with the surrounding lipid membrane. We have investigated the interaction of a drug ligand, PK11195, with
its primary protein target, the integral membrane 18 kDa translocator protein (TSPO), and model membranes
using Langmuir monolayers, quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron re-
ﬂectometry (NR). We found that PK11195 is incorporated into lipid monolayers and lipid bilayers, causing a de-
crease in lipid area/molecule and an increase in lipid bilayer rigidity. NR revealed that PK11195 is incorporated
into the lipid chain region at a volume fraction of ~10%. We reconstituted isolatedmouse TSPO into a lipid bilayer
and studied its interactionwith PK11195 using QCM-D,which revealed a larger than expected frequency response
and indicated a possible conformational change of the protein. NRmeasurements revealeda TSPO surface coverage
of 23%when immobilised to amodiﬁed surface via its polyhistidine tag, and a thickness of 51 Å for the TSPO layer.
These techniques allowed us to probe both the interaction of TSPOwith PK11195, and PK11195withmodelmem-
branes. It is possible that previously reported TSPO-independent effects of PK11195 are due to incorporation into
the lipid bilayer and alteration of its physical properties. There are also implications for the variable binding proﬁles
observed for TSPO ligands, as drug–membrane interactionsmay contribute to the apparent afﬁnity of TSPO ligands.
© 2013 Published by Elsevier B.V.1. Introduction
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vier B.V.functions, such as transport of molecules across biological membranes.
The 18 kDa translocator protein (TSPO), a protein located primarily in
the outer mitochondrial membrane, is a particularly attractive target
in the development of therapeutic drugs. It is implicated in a variety of
functions including apoptosis, steroidogenesis and immunomodulation
[1,2], and TSPO ligands have shown promise in the treatment of condi-
tions including anxiety [3], some cancers [2], neuroinﬂammation and
neurodegeneration [4,5]. TSPO and its synthetic ligands are also of diag-
nostic value for in vivo imaging, as TSPO expression is up-regulated dur-
ing neuroinﬂammation and in some types of cancer, which makes it a
valuable target for visualising the progression of these conditions [6,7].
An understanding of the structure of TSPO provides valuable insight
into its function and interaction with ligands, knowledge that is essen-
tial in the development of pharmacological interventions that target
TSPO. In particular, changes in conformation due to ligand binding and
the implication for functions such as transport need to be understood
at the molecular level. As an integral membrane protein TSPO presents
a challenge for structural investigations, and there is limited experimen-
tal data on TSPO structure. The current model of TSPO describes it as an
integral membrane protein consisting of ﬁve transmembrane alpha he-
lices [8], an extramitochondrial C-terminal containing a cholesterol
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tochondrial loops and two intramitochondrial loops [10], forming a chan-
nel that transports cholesterol across the membrane [11].
The structure and activity of a membrane protein is modulated not
only by direct interaction with its ligands, but is also inﬂuenced by the
lipid membrane environment in which it resides. There is increasing
recognition that the lipid membrane is more than an inert scaffold for
proteins, and that the arrangement of lipids in membranes carries func-
tional signiﬁcance for drug interactions. There is evidence that certain
drugs, for example some NSAIDs and anaesthetics, may modulate func-
tion by inducing physical changes in the membrane environment,
thereby affecting the conformation and function of proteins within the
membrane [12,13]. Thus, the observed effect of a drug may not be due
solely to receptor–ligand binding, but the interplay between both
drug–membrane and drug–protein interactions. In developing pharma-
cological interventionswe need anunderstanding of howdrugs interact
both with their membrane protein targets and the surrounding mem-
brane environment.
PK11195 is an isoquinoline carboxamide derivative (Fig. 1) and
nanomolar afﬁnity ligand for TSPO which has been used extensively
for imaging studies and investigating TSPO function. However, it has
also been shown to have functional effects that are independent of in-
teraction with TSPO, typically at micromolar concentrations, well
above the Kd for TSPO. There is evidence that PK11195 can sensitise
cancer cells to apoptosis and to the effects of other chemotherapeutics
via a TSPO-independent mechanism [14–17]. The exact mechanism is
unclear, but in some instances PK11195 appears tomodulate drug efﬂux
activity to overcomemultiple drug resistance [16,17]. Given the high li-
pophilicity of PK11195, and previous evidence that it affects the lipid
ﬂuidity of mitochondria [18], the ability of other compounds to
chemosensitise [19], activate apoptosis [20], and inhibit proliferation
of cancer cells by interacting with lipid membranes to change their
physical properties [21,22], it is possible that this is one mechanism
through which PK11195 induces TSPO-independent effects at high
concentration.
There is growing interest in studying the structure and function of
membrane proteins in a more natural membrane environment. It is
possible to study the function of membrane proteins reconstituted
into planar lipid bilayers using surface sensitive techniques such as
quartz crystal microbalance with dissipation monitoring (QCM-D), sur-
face plasmon resonance (SPR), and electrical impedance spectrometry
(EIS) [23]. Furthermore, the structure of planar protein/lipid bilayers
can be studied using neutron reﬂectometry (NR) [24,25]. Techniques
to form these protein/lipid bilayers have included covalently linking
an engineered protein to the surface and reconstituting lipid around
it, or inserting the protein into a pre-formed lipid bilayer [24,25]. Pro-
teins with a polyhistidine tag can be reversibly immobilised to a gold
surface that has been functionalised to a nickel or copper chelating
nitrilotriacetic acid (NTA) surface, and a lipid bilayer reconstituted
around the detergent solubilisedmembrane protein by replacing deter-
gentmoleculeswith lipid [23,26]. Studies using surface tethered protein
have shown that functions such as electron transport [26] and ligand
binding [27–29] remain intact with protein immobilisation.Fig. 1. The TSPO ligand PK11195.TSPO has been studied in model membrane environments such as
detergent micelles for investigating tertiary structure with NMR [8], li-
posomes for structural investigation with electron microscopy [30],
and more recently in lipid bilayers for investigating oligomerisation
with electron microscopy [31]. TSPO has not been studied in planar
membranes using QCM-D or NR. QCM-D provides information about
the mass, rigidity and thickness of biomimetic membranes, and can be
used to sense ligand interactions and protein conformational changes.
NR allows us to study the thickness and composition of planar model
membranes in an aqueous environment, and with the use of isotopic
contrast the lipid, protein and ligand components can be selectively
highlighted. This work was aimed at better understanding the interac-
tion of a TSPO drug ligand, PK11195, with both the TSPO and the sur-
rounding lipid membrane environment using QCM-D and NR.
2. Materials and methods
2.1. Materials
Chemicals and reagentswere purchased from Sigma-Aldrich (Sydney,
New South Wales, Australia) unless otherwise stated. Lipids and choles-
terol were purchased from Avanti Polar Lipids (Alabaster, Alabama,
USA). Silicon substrates for neutron reﬂectometry were purchased
from Crystran (Poole, Dorset, UK). Silicon substrates for SURF neutron
reﬂectometry experiments were coated with chromium and gold at
the NIST NanoFab facility (National Institute of Standards and Technol-
ogy, Gaithersburg, MD, USA). Quartz crystals coated with SiO2 or gold
were purchased from Q-Sense (Stockholm, Sweden).
2.2. TSPO expression and puriﬁcation
Cells of the BL21(DE3) Escherichia coli strain (Invitrogen/Life Technol-
ogies, Mulgrave, VIC, Australia) were transformed with the pET(TEV)
28aTSPOm vector, which produces full-length recombinant mouse
TSPO protein with an N-terminal 6xHis-tag joined by a TEV cleavage
site. The cells were grown in Fernbach ﬂasks in ModC1 media [32] con-
taining 40 μg/ml kanamycin in a shaking incubator at 37 °C at 220 rpm
to anOD600 of ~0.6 before the expression of TSPOwas induced by the ad-
dition of 1 mM isopropylβ-D-1-thiogalactopyranoside (IPTG). Cellswere
grown for a further 5 h after induction, and then harvested by centrifu-
gation at 8000 × g for 30 min at 4 °C.
The cell pellet was then resuspended in lysis buffer (50 mM HEPES,
150 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.8) with the addition of
1 mg/ml lysozyme and 5 μg/ml DNAase I. The cells were lysed by soni-
cating on ice for 6 × 30 s bursts at 40 W with an ultrasonic probe. The
lysate was centrifuged at 15,000 rpm in a Beckman JA 25.5 rotor at
4 °C for 20 min to pellet the insoluble inclusion bodies. Inclusion bodies
were thenwashed 3 times by resuspending in lysis buffer containing 1%
Triton X-100 and centrifuging at 15,000 rpm for 20 min. The ﬁnal pellet
of inclusion bodies was solubilised in binding buffer (50 mM HEPES,
150 mMNaCl, 5 mM imidazole, 1% SDS (wt/vol), pH 7.8), before ﬁnally
centrifuging at 15,000 rpm for 30 min at 20 °C. Solubilised inclusion
bodies were applied to a Qiagen SuperﬂowNi-NTA gravity ﬂow column
(Qiagen, Chadstone, VIC, Australia), washed with buffer containing
10 mM imidazole, and TSPO was eluted with 250 mM imidazole in 1%
SDS.
2.3. Preparation of liposomes and proteoliposomes
Lipid vesicles for use in QCM-D and neutron reﬂectometry were pre-
pared as follows. Stock solutions of DMPC (20 mg/ml in chloroform),
DMPE (5 mg/ml in 3:1 chloroform/methanol), cholesterol (20 mg/ml
in chloroform) or PK11195 (20 mg/ml in chloroform) were mixed ac-
cording to the desired composition, and the solvent was evaporated
under nitrogen to form a dry lipid ﬁlm. The lipids were resuspended in
Tris buffer (10 mM Tris–HCl, 150 mM NaCl, pH 7.4) to a concentration
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duce small unilamellar vesicles (SUVs). The suspension of SUVs was
then kept at 45 °C for use on the same day. The 1 mg/ml suspension
was diluted to 0.05 mg/mlwith Tris buffer for use in QCM-D. Proteolipo-
somes composed of DMPC/DMPE (9:1) and TSPO in a 4:1 (wt/wt) ratio
were prepared using a method previously described [30].
2.4. Radioligand binding
Proteoliposomes (1 μg)were incubated in a ﬁnal volume of 500 μl of
50 mMTris–HCl (pH 7.4)with 0.6 nM–10 nM tritium labelled PK11195
(3H-PK11195) in the absence or presence of 10 μMunlabelled PK11195.
Samples were incubated in triplicate for 90 min at 0 °C. The incubation
was terminated by vacuum ﬁltration overWhatmanGF/Cﬁlters, follow-
ed by 4washes with ice-cold Tris buffer. Liposomes (1 μg) without pro-
tein were incubated under the same conditions in parallel as a control.
Radioactivity trapped on the ﬁlters wasmeasured by liquid scintillation
counting. Saturation binding data were analysed using GraphPad Prism
5 (GraphPad Software, La Jolla, California, USA) to ﬁt Bmax and Kd.
2.5. Langmuir monolayers
Monolayers were formed on the surface of phosphate buffered sa-
line (PBS) in a Langmuir trough (Nima Technology, Coventry, UK)
with a Wilhelmy plate made from Whatman Chr1 chromatography
paper. DMPC, PK11195 or DMPC/PK11195 monolayers were formed
by depositing 40 μl of a 0.2 mg/ml chloroform solution across the sub-
phase surface. After all solvent had been allowed to evaporate, the bar-
rierswere closed gradually to compress themonolayerwhilemeasuring
the pressure-area isotherm. The surface pressure vs. molecular area for
eachmonolayer was recorded by the Nima software (Nima Technology,
Coventry, UK), exported and plotted in GraphPad Prism 5.
2.6. QCM-D
The Q-Sense E4 quartz crystal microbalance with dissipation moni-
toring (QCM-D) (Q-Sense, Sweden) was used for all QCM-D measure-
ments. SiO2 coated sensor crystals were cleaned by UV ozone for
15 min, followed by soaking in 2% Hellmanex solution for 10–30 min,
rinsed thoroughly with ultrapure water, dried, and ﬁnally UV cleaned
for a further 10 min. Once the sensors had been placed in the measure-
ment chamber they were further rinsed with ultrapure water, spectro-
photometric grade ethanol, and ﬁnally ultrapure water. Planar lipid
bilayers were formed on the SiO2 surface of sensor crystals using the
method of vesicle adsorption and rupture described in the literature
[33,34]. Experiments were performed at 37 °C in Tris buffer (10 mM
Tris–HCl, 150 mM NaCl, pH 7.4). A 0.05 mg/ml suspension of SUVs
was injected into each chamber at 100 μl/min, and vesicles were
allowed to incubate on the surface for up to 30 min before excess vesi-
cleswere rinsed away resulting in the formation of a planar lipid bilayer.
Gold coated sensor crystals were used for the formation of TSPO/
lipid bilayers. Gold surfaces were cleaned by exposing the surface to a
solution of H2O2/NH3/H2O (1:1:5) at 70 °C for 10 min, then rinsing
with ultrapure water and ethanol. The gold surface of the sensor crystal
was then modiﬁed with DTSP-ANTA-Cu2+ according to the method of
Giess et al. [23] in order to allow the selective binding of His-tagged
proteins to the surface. His-tagged mouse TSPO was immobilised to
the sensor surface in situ while the process was monitored in real
time using the change in frequency (Δf) and dissipation (ΔD) measure-
ments of the QCM-D. Buffer containing 0.5% SDS (wt/vol) was injected
and allowed to stabilise for approximately 10 min, followed by 900 μl
of 50 μg/ml TSPO solution containing 0.5% SDS (wt/vol) at a ﬂow rate
of 100 μl/min. The protein solution was left to incubate on the surface
for 30–60 min, before being rinsed with buffer containing 0.5% SDS
(wt/vol). A DMPC/DMPE (9:1) bilayer was formed around the
immobilised TSPO by gradually replacing the detergent surroundingthe protein with lipid. First, a solution of mixed lipid–detergent vesicles
containing 0.05 mg/ml lipid and 0.035% SDS (wt/vol) was injected into
the chamber and allowed to incubate on the surface for 30 min. A solu-
tion of lipid only vesicles at 0.05 mg/ml was then injected and allowed
to incubate on the surface for 60 min in order to allow lipidmolecules to
be incorporated into a bilayer around the protein and to replace deter-
gent molecules. This method was adapted from Giess et al. [23] and
Vacklin et al. [35]. After lipid vesicles had been incubated with the pro-
tein, excess vesicleswere rinsed offwith Tris buffer to complete protein/
lipid bilayer formation.
The interaction of lipid only and TSPO/lipid bilayerswith the TSPO li-
gand PK11195 was investigated by injecting a solution of 100 μM
PK11195 in Tris buffer over the bilayers and allowing it to incubate for
90 min. Before injecting the ligand solution, a solution containing the
same amount of ethanol (0.2%) was injected as a solvent control to dis-
tinguish between the response to the ligand and the response to the
ethanol. Both the ethanol and PK11195 solutions were injected over
bare SiO2 and DTSP-ANTA-Cu2+modiﬁed gold to check for any interac-
tion with the surface. The interaction of PK11195 with TSPO/DMPC/
DMPE (9:1) bilayers was compared with DMPC/DMPE (9:1) bilayers
formed on SiO2 because it was not possible to form them on Au-DTSP-
ANTA-Cu2+ without the immobilised TSPO.
Frequency and dissipation data were collected at the fundamental
frequency (5 MHz) of the quartz crystal and at 6 additional overtones
of the fundamental frequency. Overtones 5, 7, 9, 11, and 13 were nor-
malised and used in analysis. Traces ofΔf andΔD represent the normal-
ised 5th overtone. Sauerbrey thickness and mass were calculated using
the QTools analysis software (QSense, Sweden), using the Sauerbrey
equation [36]:
Δ mass ¼ C=n Δfrequency;
where C = –17.7 Hz ng/cm2 for a 5 MHz crystal and n is the overtone
number. Statistical analysis to compare bilayer compositions was car-
ried out using a onewayANOVA in GraphPad Prism 5, with a Bonferroni
post-hoc test. All errors reported are standard deviations.
2.7. Neutron reﬂectometry
Polished silicon blocks (80 mm × 40 mm × 15 mm (100) orienta-
tion) were used as a solid substrate for the deposition of lipid bilayers
described in Section 3.4. The blocks were cleaned in a piranha solution
of 1:4:5 (by volume) H2O2/H2SO4/H2O at 80 °C for 15–30 min, rinsed
thoroughlywith ultrapurewater, driedwith compressed air, then treat-
ed for 30 min with UV ozonolysis (caution: piranha solution is a strong
oxidant and reacts violently with organic substances). This cleaning
treatment results in a natural oxide layer of 7–20 Å thickness and
3–5 Å roughness [37]. Blocks were assembled into solid–liquid sample
cells consisting of a Teﬂon sample reservoir and aluminium fronting
and backing plates with temperature control through a circulating
water bath.
The lipids used for all neutron reﬂectometry experiments were the
chain perdeuterated d54-DMPC and hydrogenated DMPE. Lipid bilayers
composed of either d54-DMPC/DMPE (9:1) or d54-DMPC/DMPE (9:1) /
PK11195 were formed on the silicon oxide surface by depositing a
0.5 mg/ml solution of SUVs at 45 °C in buffer (10 mM Tris–HCl,
150 mM NaCl pH 7.4), then cooled to 25 °C before measurement. Neu-
tron reﬂectivity data for these bilayer samples were collected on the
Platypus time-of-ﬂight neutron reﬂectometer at the 20 MW OPAL re-
search reactor, Australian Nuclear Science and Technology Organisation
(ANSTO), Sydney, Australia [38,39], using a cold neutron spectrumwith
wavelengths of 2.8 Å–18.0 Å. Reﬂectivity was measured at angles of
0.8° and 3.0° in D2O, and 0.6° and 2.5° in CM4 (a mixture of D2O and
H2O to have an SLD of 4 × 10−6 Å−2) or CMSi (a mixture of D2O and
H2O to match the SLD of the silicon substrate, 2.07 × 10−6 Å−2) to
cover a momentum transfer (Q) range of 0.01–0.23 Å−1. To test ligand
Fig. 2. Pressure-area isotherms of DMPC and PK11195monolayers. The pressure-area iso-
therms of pure DMPC (solid line), pure PK11195 (long dashes), and a 1:1 (mol/mol) mix-
ture of DMPC and PK11195 (short dashes) were measured with a Langmuir ﬁlm balance.
Inset is a schematic of a DMPC/PK11195 (1:1)monolayer at the air-water interface. Yellow
molecules represent PK11195.
Table 1
QCM-D measurements of lipid bilayers with and without PK11195. The mean change in
frequency and dissipation associated with the formation of bilayers with and without
PK11195. The change in mass is calculated from the change in frequency using the
Sauerbrey equation.
Composition Δ Frequency (Hz) Δ Dissipation (10−6) ΔMass (ng/cm2)
DMPC −24 ± 1.2 0.9 ± 0.2 425 ± 21
DMPC/PK11195 (1:1) −22 ± 0.9 0.2 ± 0.2 389 ± 16
DMPC/DMPE (9:1) −26 ± 0.6 0.9 ± 0.2 460 ± 11
DMPC/DMPE/
PK11195 (9:1:10)
−24 ± 0.6 0.5 ± 0.2 425 ± 11
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100 μMwas injected over the bilayer, incubated for 90 min, and reﬂec-
tivity data were collected again in D2O and CMSi solvents.
Silicon blocks (100 mm diameter × 10 mm height) coated with
chromiumand goldwere used for TSPO/lipid bilayermeasurements de-
scribed in Section 3.7. The blocks were cleaned with 2% Hellmanex,
rinsed thoroughly with ultra-pure water, isopropanol, and dried under
nitrogen. The gold surface of each block used was then modiﬁed in
order to bind His-tagged TSPO using the methods described in
Section 2.6. Blocks were assembled into circular solid–liquid sample
cells consisting of a Teﬂon reservoir, aluminium backing plates, and
inlet and outlet valves connected to an HPLC pump for automatic sam-
ple injection and solvent exchange. Sample cells were maintained at
25 °C.
The modiﬁed gold surfaces in D2O were measured before 4 ml of
50 μg/ml TSPO in Tris buffer containing 0.5% SDS (wt/vol) was injected
and incubated on the surface for 60 min. Excess protein was rinsed off
with Tris + 0.5% SDS before measuring the reﬂectivity of the TSPO/
SDS layer. A lipid bilayer was then reconstituted around the TSPO
layer by ﬁrst injecting a solution of 0.1 mg/ml d54-DMPC/DMPE (9:1)
vesicles solubilised in 0.035% SDS (wt/vol) in Tris buffer and leaving
the mixture to incubate for 60 min. Reconstitution was completed by
injecting a 0.1 mg/ml d54-DMPC/DMPE (9:1) vesicle solution, incubat-
ing for 60 min, and rinsingwith Tris buffer to remove excess vesicles be-
fore measuring the reﬂectivity of the TSPO/lipid bilayer.
Neutron reﬂectivity measurements at each stage of the construction
of a TSPO/lipid bilayer described above were carried out on the SURF re-
ﬂectometer located at the ISIS spallation neutron source (Rutherford Ap-
pleton Laboratories, Didcot, Oxfordshire, UK). Measurements on SURF
used neutrons with wavelengths of 0.5 Å–6.8 Å. Reﬂectivity was mea-
sured at angles of 0.35°, 0.8° and 1.8° to cover a Q of 0.01–0.49 Å−1. At
each stage of sample development the reﬂectivitywasmeasured in 3 sol-
vent contrasts: D2O, H2O, and contrast matched gold (CMAu, nSLD of
4.5 × 10−6 Å−2). The bare modiﬁed surface was measured in D2O only.
Reﬂectivity data from both Platypus and SURF were reduced at the
beamline and later modelled using the MOTOFIT analysis program
[40]. MOTOFIT uses the Abeles matrix method to produce a slab model
of the reﬂectivity data with the thickness, SLD, solvent penetration
and roughness of each layer. Data from multiple solvent contrasts for
each sample were co-reﬁned to arrive at one model to ﬁt all data. The
volume fraction of each componentwas calculated using the theoretical
SLDs given in Table S1 of the Supplementary Material. Errors given are
the standard deviations reported by MOTOFIT.
3. Results and discussion
3.1. PK11195 in lipid monolayers
We ﬁrst assessed the possible interaction of PK11195 with lipids in
monolayers at the air–water interface using a Langmuir ﬁlm balance.
A comparison of the pressure-area isotherms of pure DMPC, pure
PK11195 and DMPC/PK11195(1:1) is given in Fig. 2. The DMPC iso-
therm indicates that the monolayer is primarily in the liquid-
expanded phase, and does not exhibit any clear phase transitions at
this temperature. The PK11195 isotherm indicates that it forms amono-
layer at the air–water interface upon compression and is in the liquid-
condensed phase at molecular areas below 13 Å2. The pure PK11195
monolayer reaches small values of surface pressure when compared
to the pure DMPC monolayer, but is comparable to isotherms obtained
for other drug ligands [41]. There is evidence of adsorption of
PK11195 to the air–water interface; thus, it has potential to be incorpo-
rated into a monolayer of lipids.
The pressure-area isotherm of amixed DMPC/PK11195 (1:1)mono-
layer indicates that the inclusion of PK11195 in the DMPC monolayer
caused a shift of the DMPC isotherm to smaller molecular areas, and a
shift from the liquid-expanded to the liquid-condensed phase atmolecular areas below 60 Å2 (Fig. 2). The same total amount of DMPC
was deposited on the surface in each case, so it is likely that the
PK11195 is causing the DMPC monolayer to become more compact, as
illustrated in Fig. 2 inset. At surface pressures of 35 mN/m, similar to a
lipid bilayer [42], the area/molecule of the DMPC monolayer is 58 Å2,
while the area/DMPC molecule of the DMPC/PK11195 (1:1) monolayer
is 44 Å2.
This effect has been observed in mixed DMPC/cholesterol mono-
layers, as the cholesterol increases the order of the acyl chains and con-
denses the monolayer [43]. In addition, there is evidence that
hexadecanol can replace cholesterol in DMPC monolayers to produce
the same or greater effect [44]. In general, a drug that condenses a
lipid monolayer is likely to insert among the acyl chains, increasing
their order and packing [45]. Given that other drug ligands and organic
compounds [46] can exert a similar effect to cholesterol, it is likely that
PK11195 is also inserted into the acyl chain region of the DMPC mono-
layer to cause a decrease in molecular area of the DMPC.
3.2. Incorporation of PK11195 into lipid bilayers
Next, we pre-incorporated the TSPO ligand PK11195 into lipid vesi-
cles to investigate (using QCM-D)whether a planar lipid bilayer formed
frommixed lipid/PK11195 vesicles differed from one formed using lipid
only vesicles. The change in frequency (Δf) and dissipation (ΔD) mea-
sured by QCM-D after stable planar bilayer formation is given in
Table 1 for each vesicle composition. Typical traces of Δf and ΔD during
bilayer formation are given in Fig. S1 and are in good agreement with
QCM-D data for similar lipid compositions [47].
In the case of both DMPC and DMPC/DMPE (9:1) vesicles, the incor-
poration of PK11195 produced bilayers with a ﬁnal Δf and ΔD that was
smaller than the lipid only bilayers (p b 0.05) (Table 1). The smaller ΔD
of the bilayers containing PK11195 indicates that the presence of the li-
gand produces a more rigid bilayer; similar to an effect observed when
glycolipids were incorporated into egg PC bilayers [48]. The increased
Table 2
QCM-D measurements of the interaction of PK11195 with lipid bilayers. The mean peak
change in frequency, dissipation and Sauerbrey mass of lipid bilayers and bare SiO2 asso-
ciated with exposure to PK11195.
Composition Δ Frequency (Hz) Δ Dissipation (10−6) ΔMass (ng/cm2)
SiO2 surface −0.2 ± 0.3 0.01 ± 0.02 4 ± 5
DMPC/DMPE (9:1) −1.5 ± 0.1 0.90 ± 0.13 27 ± 2
DMPC/DMPE/
PK11195 (9:1:10)
−0.8 ± 0.3 0.87 ± 0.13 14 ± 5
DMPC/DMPE/
chol (8:1:1)
−1.9 ± 0.1 0.91 ± 0.03 34 ± 2
DMPC/DMPE (3:2) −1.4 ± 0.2 1.08 ± 0.17 25 ± 4
Fig. 3.QCM-D trace of PK11195 interactionwith a lipid bilayer. A typical trace of frequency
(f) (blue solid line) and dissipation (D) (red dashed line) during the exposure of a lipid bi-
layer to 0.2% ethanol and 100 μM PK11195. The trace starts after the formation of a stable
DMPC/DMPE (9:1) bilayer on SiO2. There are a small decrease in f and increase in Dwhen
0.2% ethanol is introduced (point A). Subsequent injection of PK11195 (point B) results in
a further decrease in f and increase in D, both of which peak soon after exposure to
PK11195, followed by a gradual return towards 0.2% ethanol values during incubation.
When the PK11195 (point C) and ethanol (point D) are rinsed away with buffer, the f
and D signals appear to be slightly higher and lower, respectively, than before exposure
to PK11195.
1023C.R. Hatty et al. / Biochimica et Biophysica Acta 1838 (2014) 1019–1030rigidity of themixed lipid/PK11195 bilayersmay represent a decrease in
ﬂuidity, an effect that has been observedwhen cholesterol is incorporat-
ed into PC bilayers [49]. It is likely that the ﬂuidity of the lipid/PK11195
bilayers was reduced due to increased ordering of the lipid chains [50],
an interpretation that is in agreement with the condensing effect of
PK11195 on DMPC monolayers we observed in Fig. 2.
The ﬁnal Δf for bilayers containing PK11195 was smaller than for
lipid only bilayers, giving a smaller value for Sauerbrey mass (Table 1).
The deposited mass measured by QCM-D includes coupled water due
to hydration of the bilayer, and it is difﬁcult to distinguish the mass
due to lipid from the mass due to hydration without the use of optical
techniques [51]. Thus, it is possible that the decrease in Sauerbrey
mass of the lipid/PK11195 bilayers could be due to a smaller mass of
the bilayer itself or to decreased hydration of the bilayer compared to
lipid only.
If the measuredmass purely reﬂected themass of the bilayer, then a
greater mass for the lipid/PK11195 bilayer would be expected if it were
condensed compared to a lipid only bilayer, as the surface could accom-
modate more molecules [48]. Therefore, it is possible that the smaller
mass of the lipid/PK11195 bilayers is due to a decrease in hydration,
just as the addition of cholesterol to lipid bilayers results in decreased
interchain hydration of the lipid [49,50,52]. A decrease in hydration of
the lipid chain region would be consistent with increased ordering of
the lipid [50], as indicated by the increased rigidity of bilayers contain-
ing PK11195.
The differences between the bilayers with and without PK11195 in-
dicate that the PK11195 has been incorporated into the bilayer, causing
a change in the bilayer structure. The difference in structure between a
lipid bilayer with and without PK11195 was further investigated using
neutron reﬂectometry and is discussed in Section 3.4.
3.3. Interaction of PK11195 with lipid bilayers
The above results indicate that PK11195 interacts with lipid mole-
cules and can be pre-incorporated into lipid monolayers and bilayers.
Hence, we aimed to further investigate this interaction by looking at
whether PK11195 in solution would interact with an already formed
supported lipid bilayer. The interaction of PK11195 with bilayers com-
posed of DMPC/DMPE (3:2) and DMPC/DMPE/cholesterol (8:1:1), cho-
sen to reﬂect the major components of the outer mitochondrial and
plasma membranes respectively, were tested in addition to the DMPC/
DMPE (9:1) and DMPC/DMPE/PK11195 (9:1:10) bilayers used in
Section 3.2.
The peakΔf,ΔD, and Sauerbreymass during exposure of each bilayer
composition to PK11195 is given in Table 2. There was a signiﬁcantly
greater Δf and ΔD when PK11195 was injected over all lipid bilayer
compositions when compared to the bare surface (p b 0.05), indicating
that the interaction was particular to the lipids rather than SiO2.
The magnitude of the interaction differed between some lipid com-
positions (Table 2). In particular, there was a signiﬁcantly smaller
PK11195 induced Δf for bilayers already containing PK11195 when
compared to those without (p b 0.05). This may indicate that the bilay-
er is already occupied by pre-incorporated PK11195 leaving little room
for further incorporation of PK11195 from solution. The additional mass
after exposure of DMPC/DMPE/PK11195 (9:1:10) bilayers to PK11195
was approximately half that of the other lipid compositions (Table 2).
Hence, it appears that PK11195 is present in the bilayer after pre-
incorporation and lowers the amount of PK11195 that interacts with
the bilayer from solution.
The PK11195 induced Δf did not differ between the DMPC bilayers
with varying amounts of DMPE (Table 2). Therewas a signiﬁcantly larg-
er response for DMPC/DMPE/cholesterol (8:1:1) than for DMPC/DMPE
(3:2) (p b 0.05), but no statistically signiﬁcant difference between the
PK11195 induced Δf in DMPC/DMPE/cholesterol (8:1:1) vs. DMPC/
DMPE (9:1) bilayers. However, the Δf between DMPC/DMPE (9:1) and
DMPC/DMPE (3:2) are similar, and considering there is a differencebetween DMPC/DMPE (3:2) and DMPC/DMPE/cholesterol (8:1:1) it is
possible that with further investigation a difference between DMPC/
DMPE (9:1) and DMPC/DMPE/cholesterol (8:1:1) may emerge.
The Δf and ΔD after exposure of lipid bilayers to PK11195 tended to
peak very soon after injection of the ligand (Fig. 3, point B). This indi-
cates that there is rapid association of the PK11195 to the lipid bilayer
[53], and is unlikely to purely reﬂect a change in the viscosity of the
bulk solvent as the effect was not present on the bare surface. After
reaching a peak, both the Δf and ΔD signals began to move towards
pre-PK11195 values (Fig. 3, point B to C). This effect was not observed
when the bilayers were exposed to 0.2% ethanol or buffer only for the
same amount of time, indicating that it is not due to drift in the signal.
The changes inΔf andΔD values during incubation (Fig. 3, point B to
C) indicate a process of PK11195 association and incorporation into the
bilayer [54,55]. The initial peak signals indicate the association of
PK11195 with the surface of the bilayer, as a layer of PK11195 on top
of the bilayer is expected to cause increased mass and an increased
ΔD [55]. The decrease in ΔD values over time (Fig. 3, point B to C) indi-
cates a structural rearrangement of the bilayer and associated PK11195
[56], and may reﬂect PK11195 being gradually incorporated from the
surface of the bilayer into the bilayer [54,55]. The gradual increase in
Δf values (Fig. 3, point B to C) indicates a slight loss ofmass from the sur-
face, possibly because of a loss of water from the bilayer as PK11195 is
incorporated, or the dissociation of excess PK11195 from the bilayer
surface as the binding and incorporation reach equilibrium [57].
After PK11195 and ethanol had been completely rinsed from the
lipid bilayers, Δf and ΔD values tended to be higher and lower, respec-
tively, than before exposure to PK11195 (Fig. 3, point D). The slight in-
crease in Δf values indicates a small loss of mass, and is similar to the
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Fig. 4. Neutron reﬂectivity measurements of lipid bilayers with PK11195. (A) Neutron re-
ﬂectivity proﬁles of a d54-DMPC/DMPE (9:1) bilayer before (black) and after (red) expo-
sure to 100 μM PK11195, and a d54-DMPC/DMPE (9:1) /PK11195 bilayer (blue)
measured in D2O. Points and error bars are measured data, and lines are ﬁts to the data.
(B) Comparison of scattering length density proﬁles of lipid bilayers with and without
PK11195 in D2O. (C) Schematic of the structure of a d54-DMPC/DMPE (9:1) bilayer with
incorporated PK11195.
1024 C.R. Hatty et al. / Biochimica et Biophysica Acta 1838 (2014) 1019–1030observed effect of pre-incorporating PK11195 into bilayers. The same
was the case for ΔD values, with a smaller ﬁnal ΔD indicating a more
rigid bilayer, as for bilayers with pre-incorporated PK11195. Overall,
the changes in Δf and ΔD values during exposure of lipid bilayers to
PK11195 indicate that it associated with the bilayer and caused some
structural change [54,55,57].
While the PK11195 induced ΔD was greater for lipid bilayers than
for the bare surface (Table 2), the change did not differ between lipid
compositions of the non-PK11195 pre-incorporated bilayers. This indi-
cates that the PK11195 adsorbs to lipid bilayers in a similar way regard-
less of lipid composition [54]. The ΔD is likely to reﬂect a change in
overall structure of the adsorbed layer, and possibly the addition of a
PK11195 layer on the surface of the lipid bilayer. The consistent ΔD
across lipid bilayer compositions (Table 2) indicates that themodeof in-
teraction is the same, while the difference in Δf indicates that the
amount of associated ligand differs between lipid compositions
[54,55]. The effect of PK11195 interaction on lipid bilayer structure
was investigated further with neutron reﬂectometry, and results are
presented in Section 3.4.
3.4. Structure of lipid bilayers with PK11195
The thickness and composition of a d54-DMPC/DMPE (9:1) bilayer
before and after exposure to PK11195, and a d54-DMPC/DMPE (9:1) bi-
layer with pre-incorporated PK11195, were investigated with neutron
reﬂectometry to further characterise the changes seen with QCM-D.
The reﬂectivity proﬁles of each system in D2O are given in Fig. 4. The re-
ﬂectivity proﬁles and ﬁts at each solvent contrast measured are given in
Fig. S2 (d54-DMPC/DMPE (9:1)), Fig. S3 (d54-DMPC/DMPE (9:1) /
PK11195) and Fig. S4 (d54-DMPC/DMPE (9:1) + PK11195) of the Sup-
plementary Material. In each case the bilayer itself was ﬁtted using all
solvent contrasts to a three layer model consisting of the inner lipid
headgroup, lipid chain region, and the outer lipid headgroup. The details
of modelled parameters for each sample are given in Table 3, and
Table S2 of the Supplementary Material.
The volume fractions of lipid, solvent and PK11195 in each layer
were calculated from the ﬁtted nSLDs and the molecular nSLDs using
the equation:
ρlayer ¼ ϕlipidρlipid þ ϕPK11195ρPK11195 þ ϕsolventρsolvent:
The volume fraction of PK11195 in the lipid headgroups, if it was
present in this region, could not be calculated due to the similarity of
the nSLD of PK11195 to the headgroups (Supplementary Table S1). It
was also difﬁcult to distinguish the contribution of PK11195 to the
nSLD of the headgroup regions from the solvent penetration.
The nSLD of the lipid chain region of the d54-DMPC/DMPE (9:1) /
PK11195 bilayer, and the d54-DMPC/DMPE (9:1) bilayer after exposure
to PK11195, was reduced compared to that of the d54-DMPC/DMPE
(9:1) bilayer (Fig. 4B). In each case the nSLDof the chain regions indicat-
ed a volume fraction of approximately 10% PK11195 (Table 3). A similar
volume fraction of PK11195 in the case of both pre-incorporation and
interaction with a pre-formed bilayer indicates that there may be a pre-
ferred molar ratio for the lipid to PK11195 interaction.
The surface excess (Γ) of both PK11195 and lipid was calculated
using the equation:
Γ ¼ ϕ dMð Þ= V  NAð Þ
whereφ is volume fraction, d is thickness,M is molar mass, and V ismo-
lecular volume. Molecular volumes of 1101 Å3 [58] for lipid and 323 Å3
for PK11195 (calculated with the Molinspiration Property Calculator
[59]) were used. The surface excesses of PK11195 and lipid (Table 3)
for the d54-DMPC/DMPE (9:1) bilayer after interaction with PK11195
are close to the Sauerbrey mass values calculated from QCM-D results
(Tables 1 and 2). The calculated surface excess gives a PK11195 tolipid molar ratio of 1:9.6, which is similar to the ratio of 1:8.2 from
QCM-D results. Likewise, the surface excesses of PK11195 and lipid for
the d54-DMPC/DMPE (9:1)/PK11195 bilayer give a PK11195 to lipid
molar ratio of 1:10.3. Results from both neutron reﬂectivity and QCM-
D are in good agreement and further indicate a preferred PK11195 to
lipid molar ratio for association. The consistent molar ratio of PK11195
incorporation may also explain why there was less binding of
PK11195 from solution with bilayers already containing PK11195 ob-
served in QCM-D experiments.
The solvent volume fraction in the chain region of the d54-DMPC/
DMPE (9:1)/PK11195 bilayer was slightly higher than that of the
d54-DMPC/DMPE (9:1) bilayer (Table 3), which could indicate
Table 3
Neutron reﬂectivitymeasurements of lipid bilayerswith andwithout PK11195.Modelled parameters derived fromneutron reﬂectivity data for a d54-DMPC/DMPE (9:1) bilayer before and
after exposure to PK11195, and a d54-DMPC/DMPE (9:1) /PK11195 bilayer. The thickness (d), volume fraction (φ) and surface excess (Γ) are given for each layer.
d (Å) φlipid φsolvent φPK11195 Γlipid ng/cm2 ΓPK11195 ng/cm2
d54-DMPC/DMPE (9:1)
Inner headgroup 9 ± 2 0.74 0.26 – 520 ± 61 –
Chain region 30 ± 3 0.98 0.02 –
Outer headgroup 9 ± 2 0.66 0.34 –
d54-DMPC/DMPE (9:1) + 100 μM PK11195
Inner headgroup 8 ± 2 0.76 0.24 – 457 ± 53
Chain region 30 ± 3 0.88 0.02 0.10 23 ± 3
Outer headgroup 9 ± 2 0.66 0.34 –
d54-DMPC/DMPE (9:1) /PK11195
Inner headgroup 9 ± 2 0.64 0.36 – 471 ± 55
Chain region 31 ± 3 0.87 0.05 0.08 22 ± 3
Outer headgroup 9 ± 2 0.75 0.25 –
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coverage [60]. The solvent penetration into the headgroups of the
d54-DMPC/DMPE (9:1) /PK11195 bilayer indicates a similar level of
hydration as the d54-DMPC/DMPE (9:1) bilayer (Table 3). The nSLD
and solvent penetration in the lipid headgroups of d54-DMPC/
DMPE (9:1) after exposure to PK11195 remained essentially the
same as before exposure (Table 3).
The thickness of each layer of the d54-DMPC/DMPE (9:1) /PK11195
bilayer is essentially the same (within error) as that of the d54-DMPC/
DMPE (9:1) bilayer (Table 3). The inner and outer head groups of both
compositions had a thickness of 9 ± 2 Å, while the chain regions of
d54-DMPC/DMPE (9:1) and d54-DMPC/DMPE (9:1) /PK11195 were
30 ± 3 Å and 31 ± 3 Å thick respectively. The comparison of QCM-D
data for lipid bilayers presented in Section 3.2 indicates that the incor-
poration of PK11195 caused bilayers to become more rigid at 37 °C,
and possibly shifts ﬂuid bilayers towards the gel phase. A shift towards
the gel phase is typically accompanied by an increase in acyl chain thick-
ness [58]. However, an increase in thickness was not observed in the
neutron reﬂectivity data. This may be because the data were measured
at 25 °C rather than 37 °C, whichwas necessary for better bilayer stabil-
ity on the silicon surface over the requiredmeasurement times. At 25 °C
the DMPC/DMPE lipid mixture is likely to be in a mixed gel and liquid
crystalline phase [61], with an acyl chain thickness that is approaching
the theoretical maximum [62,63]. Hence, the incorporation of PK11195
may have a less pronounced effect than at 37 °C. It is also possible that
any change in thickness may be too small to detect given the error in
the measurement.
The thickness of the d54-DMPC/DMPE (9:1) bilayer was also un-
changed by interaction with PK11195, as was the case for pre-
incorporated PK11195 bilayer (Table 3). The QCM-D data for PK11195
interaction with lipid bilayers (Section 3.3) indicated that a layer of
PK11195 may have been adsorbed to the surface of the bilayer initially,
before incorporating into the bilayer. However, an additional layer
above the lipid bilayer to represent PK11195 could not be ﬁtted to the
neutron reﬂectivity data. It is possible that if there was a layer of
PK11195 on the bilayer surface it did not have enough SLD contrast to
be detected. It is also possible that the PK11195 initially adsorbed to
the surface of the bilayer had either been incorporated into the bilayer
or disassociated by the time of measurement, as measurements were
made after a 90 min incubation period.
Overall, we detected a change in composition between the d54-
DMPC/DMPE (9:1) and d54-DMPC/DMPE (9:1) /PK11195 bilayers
using neutron reﬂectometry, but observed no signiﬁcant change in bi-
layer thickness. Additionally, it appears that PK11195 is incorporated
into a d54-DMPC/DMPE (9:1) bilayer from solution in much the same
way as when pre-incorporated into lipid vesicles before planar bilayer
formation. A consistent PK11195 volume fraction of around 10% in the
lipid chain regions of both systems indicates that there is a preferred
ratio of lipid to PK11195. The combination of our results from Langmuirmonolayers, QCM-D and NR provide evidence that PK11195 is incorpo-
rated into lipid bilayers andmonolayers and suggest an interactionwith
lipids that is similar to that of cholesterol. The decreased area/molecule
and increased rigidity of monolayer and bilayers with PK11195 suggest
that the ligand is incorporated into the lipid chains, increasing their
order and reducing ﬂuidity, as observed previously for cholesterol
[64]. It is interesting to note that Miccoli et al. [18] found an increase
in mitochondrial membrane ﬂuidity after exposure to 10 nM PK11195
for 24 h, which was regulated via binding to TSPO. Our results may
differ because they reﬂect a direct and acute interaction between the li-
gand and lipid in the absence of TSPO, and at a higher ligand concentra-
tion. Other recent studies have highlighted the effect of small molecule
incorporation on lipid membrane properties and the implications this
has in disease [64], and our results suggest this as one mechanism
through which PK11195 exerts its TSPO-independent effects at micro-
molar concentrations.
3.5. Reconstitution of mouse TSPO into a supported lipid bilayer
Protein/lipid bilayers were formed using the general method illus-
trated in Fig. 5. The ﬁrst step in reconstituting TSPO into a DMPC/
DMPE (9:1) bilayer is immobilising the protein to a modiﬁed gold sur-
face, whichwe followed bymeasurementwithQCM-D. Our results indi-
cate that the TSPOwas immobilised to the Au-DTSP-ANTA-Cu2+ surface
via its His-tag in a reversible manner, and that TSPO binding was
displaced by imidazole (Fig. S5 in Supplementary Material).
We then monitored the complete process of forming a TSPO and
DMPC/DMPE (9:1) bilayer (Fig. 6). The Δf, ΔD, Sauerbrey mass and
Sauerbrey thickness values at the major stages of this process are
given in Table 4. The small decrease in Δf and increase in ΔD observed
after the introduction of 0.5% SDS (Fig. 6, point A) indicates some ad-
sorption of SDS to the crystal surface, an effect which has also been ob-
served for n-Dodecyl β-D-maltoside (DDM) on a gold surface with the
same modiﬁcations [23].
The decrease in Δf as a result of incubating TSPO on the surface indi-
cates adsorption of the protein (Fig. 6, point B to D). The molecular area
of a TSPOmonomer is estimated to be 540 Å2, based on amolecular area
of 1080 Å2 for a dimer of its homologue TspO from Rhodobacter
sphaeroides [65]. The molecular weight of the engineered TSPO is
21 kDa. Using these values for molecular weight and area of the TSPO,
a full coverage monolayer of TSPO would theoretically result in a Δf of
−37 Hz. The Δf due to TSPO/SDS adsorption was −34 Hz (Fig. 6,
point B to D), which is close to the expected value. This Δf value is com-
parable to other studies of protein adsorption usingQCM-D,whichwere
in the range of−13 to−54 Hz depending on themolecularweight and
molecular area of the protein [27–29].
The ΔD value reaches 1.9 × 10−6 after protein adsorption (Table 4).
Other studies have reported ΔD values as high as 15.8 × 10−6 for a vis-
coelastic protein layer, and 1.5 × 10−6 for a more rigid protein layer
Fig. 5. Schematic of the process of protein/lipid bilayer formationwith TSPO. The gold sur-
face is modiﬁed to allow the reversible binding of His-tagged proteins by ﬁrst exposing to
dithiobis (N-succinimidyl propionate) (DTSP) to create a N-hydroxy succinimide (NHS)
ester functionalised surface. Next, the NHS surface is coupled with nitrilotriacetic acid
groups bearing a terminal amino group (ANTA). The surface is activated by complexation
of Cu2+, and is ready to bind His-tagged protein. TSPO solubilised in detergent is then
immobilised to the modiﬁed gold surface via its His-tag. The detergent is gradually re-
placed by lipid, and a lipid bilayer is reconstituted around the immobilised TSPO.
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TSPO/SDS layer gives a value of 5.7 nm, which is in the range expected
for a protein such as TSPO that spans a phospholipid bilayer membrane
[10].Fig. 6.QCM-D trace of the process of TSPO/DMPC/DMPE (9:1) bilayer formation. A typical
trace of frequency (f) (blue solid line) and dissipation (D) (red dashed line) during the for-
mation of a TSPO/DMPC/DMPE (9:1) bilayer. The process commenced with injection of
buffer containing 0.5% SDS (A), followed by injection of TSPO in 0.5% SDS (B) which was
allowed to incubate on the surface before rinsing off excess protein (C). The reconstitution
of lipid around the protein started by injecting a solution of DMPC/DMPE (9:1) vesicles
solubilised in SDS (D). To complete the reconstitution process a solution of DMPC/DMPE
(9:1) vesicles was injected (E), followed by rinsing to remove excess vesicles (F).We reconstituted a DMPC/DMPE (9:1) bilayer around immobilised
TSPO by gradually replacing SDS with lipid. When SDS solubilised lipid
vesicles were injected there was a decrease in Δf and ΔD (Fig. 6, point
D). This may indicate that space between bound TSPO/SDS was being
ﬁlled by lipid molecules, and that the TSPO/SDS/lipid layer was begin-
ning to adopt a more rigid structure. A solution of DMPC/DMPE (9:1)
vesicles was then injected to complete the removal of SDS (Fig. 6,
point E). The spike in Δf and ΔD observed at this point indicates the ad-
sorption and then rupture of lipid vesicles, as seen when forming lipid
only bilayers on a SiO2 surface [33].
The stable Δf value of TSPO/DMPC/DMPE (9:1) was slightly higher
than TSPO/SDS, with a lower ΔD value (Table 4), suggesting that the
TSPO/DMPC/DMPE (9:1) layer had a smaller mass than the TSPO/SDS
layer, and was more rigid. It is likely that replacing SDS micelles with
a lipid bilayer caused the layer to become more rigid and TSPO to
adopt a different conformation, as reconstituting TSPO into a more nat-
ural lipid layer is likely to result in refolding of the protein [30].
We also expect a TSPO/DMPC/DMPE (9:1) layer to have a smaller
mass than a TSPO/SDS layer at constant protein coverage, if the volume
of the layer not occupied by protein was entirely composed of SDS or
lipid molecules. The protein surface coverage was approximately 50%,
based on a mass of 537 ng/cm2, and molecular areas of 540 Å2 for
TSPO and 50 Å2 on average for DMPC/DMPE (9:1). The Sauerbrey thick-
ness of the TSPO/DMPC/DMPE (9:1) layer is 5.1 nm, which is reasonable
given the thickness of a DMPC/DMPE (9:1) bilayer (Section 3.4), the es-
timated thickness of TSPO in the membrane plane [65], and values re-
ported for other protein/lipid bilayers on the same surface [23]. Overall,
our results indicate that TSPO in SDS was successfully immobilised to
an Au-DTSP-ANTA-Cu2+ surface, and that gradual replacement of SDS
with DMPC/DMPE (9:1) resulted in the formation of a TSPO/DMPC/
DMPE (9:1) layer of expected mass and thickness.3.6. Ligand interactions of reconstituted TSPO
We ﬁrst assessed the activity of recombinant TSPO by its ability to
bind 3H-PK11195 when reconstituted into DMPC/DMPE (9:1) lipo-
somes (Fig. 7). The Kd value of 7.3 nM was similar to that obtained for
TSPO proteoliposomes elsewhere [30], and is in the afﬁnity range typi-
cally reported for PK11195 binding to TSPO in native membrane prepa-
rations [1].
We then examined the interaction of PK11195 with reconstituted
TSPO/DMPC/DMPE (9:1) bilayers, formed as described in Section 3.5,
using QCM-D. Changes in f and D during exposure to PK11195 are
given in Table 5. There was no signiﬁcant difference in either the Δf or
ΔD responses to ethanol between the surface conditions. However, ex-
posure of TSPO/DMPC/DMPE (9:1) bilayers to PK11195 caused a signif-
icantly larger Δf when compared to the bare Au-DTSP-ANTA-Cu2+
surface or DMPC/DMPE (9:1) bilayers (p b 0.0001). This indicates that
the presence of TSPO changed the interaction between the Au-DTSP-
ANTA-Cu2+ surface or DMPC/DMPE (9:1) bilayer and PK11195.
The response is much larger than expected for PK11195 binding to
the TSPO. The change inmass if there were one to one binding between
PK11195 and TSPO, even at a protein surface coverage of 100%, would
result in a Δf of less than−1 Hz. The unexpectedly large Δf could be
due to ligand-induced conformational changes of the TSPO, as similar
observations were made in QCM-D studies of ligand binding to
oestrogen receptors [28,29] and glucose/galactose receptors [27]
immobilised to gold. In these studies, the magnitude of Δf varied with
different ligands, and they hypothesised that the larger than expected
Δf responses were due to ligand-induced conformational changes of
the protein [27–29]. It has been suggested that TSPO acts as a cholester-
ol transport channel, and that binding of ligands such as PK11195 may
drive the conformational changes necessary for TSPO to transport cho-
lesterol [67]. There is also evidence that PK11195 stabilises the tertiary
fold of isolated TSPO in detergent micelles [8]. Hence, the response we
Table 4
QCM-Dmeasurements during the formation of a TSPO/lipid bilayer. The frequency and dissipation response of a Au-DTSP-ANTA-Cu2+ coated quartz crystal wasmeasured after exposure
to 0.5% SDS, after the immobilisation of TSPO/SDS, and after the formation of a TSPO/DMPC/DMPE (9:1) bilayer. The mass and thickness were calculated using the Sauerbrey equation.
Values given are means ± SD of at least 7 independent measurements.
Composition Δ Frequency (Hz) Δ Dissipation (10−6) ΔMass (ng/cm2) Δ Thickness (nm)
SDS only −2 ± 1 1.0 ± 0.2 41 ± 9 0.4 ± 0.1
TSPO/SDS −34 ± 2 1.9 ± 0.3 593 ± 41 5.7 ± 0.4
TSPO/lipid −30 ± 2 0.5 ± 0.2 537 ± 38 5.1 ± 0.4
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others upon exposure to PK11195.
The largeΔf could also be the result of increasedwater content of the
TSPO/DMPC/DMPE (9:1) bilayer, possibly via a change in lipid bilayer
hydration or in conformation of TSPO. For example, the opening of
TSPO channels in the TSPO/DMPC/DMPE (9:1) bilayer could increase
the amount of water penetrating into the protein/lipid bilayer, thereby
increasing its mass.
The ΔD as a result of PK11195 exposure was signiﬁcantly greater for
the TSPO/DMPC/DMPE (9:1) bilayer as compared to the Au-DTSP-
ANTA-Cu2+ surface (p b 0.01), but no different from the DMPC/DMPE
(9:1) bilayer (Table 5). This suggests that the effect of PK11195 on ΔD
is not speciﬁc to a bilayer containing TSPO, and may reﬂect an effect
on the lipid. Data presented in Section 3.3 suggest an interaction be-
tween PK11195 and lipid bilayers, albeit with a signiﬁcantly smaller Δf
than in the presence of TSPO. It is likely that the interaction between
PK11195 and lipidmakes a small contribution to the overallΔf response
of the TSPO/DMPC/DMPE (9:1) to PK11195 exposure, and that the con-
tribution of lipid-PK11195 interaction to ΔD is indistinguishable from
that of TSPO-PK11195 interaction. Previous studies of small molecule
binding to immobilised protein have not measured ΔD [27–29]; there-
fore, it is difﬁcult to make a comparison.
3.7. Characterisation of surface immobilised TSPO with neutron
reﬂectometry
We have characterised the structure of immobilised TSPO on an Au-
DTSP-ANTA-Cu2+ surface using neutron reﬂectometry. The reﬂectivity
of surface immobilised TSPO in SDS is given in Fig. 8, with the corre-
sponding SLD proﬁles. The data were ﬁtted to a ﬁve layermodel, includ-
ing the SiO2, Cr, Au and DTSP-ANTA-Cu2+ layers, and one layer for the
TSPO (Table S3 in Supplementary Material).
The thickness of the DTSP-ANTA-Cu2+ modiﬁcation was 14 ± 2 Å,
which is close to the estimated value of 10 Å [23,26], and the range expect-
ed from the dimensions of the molecules. The nSLD of the DTSP-ANTA-Fig. 7. Saturation isotherm of 3H-PK11195 binding to TSPO proteoliposomes. TSPO was
reconstituted into DMPC/DMPE (9:1) liposomes in a 4:1 (w/w) lipid to protein ratio.
There is speciﬁc binding to proteoliposomes, whereas no speciﬁc binding was detected
for liposomes without TSPO. Scatchard analysis gives a Kd of 7.4 ± 3 nM and Bmax of
6.4 ± 1.5 pmol/mg for proteoliposomes, mean and SD from three independent
experiments.Cu2+ modiﬁcation was 2.67 × 10−6 Å−2, which is within the range of
theoretical nSLDs of each component (DTSP = 3.40 × 10−6 Å−2,
ANTA = 2.21 × 10−6 Å−2, and CuSO4 = 4.86 × 10−6 Å−2). The thick-
ness and SLD of the modiﬁcation layer did not change signiﬁcantly with
the addition of TSPO, and co-reﬁnement of data taken at multiple solvent
contrasts revealed a solvent penetration of approximately 5%.
The thickness of immobilised TSPO in SDSmodelled from reﬂectom-
etry data was 51 ± 2 Å (Fig. 8). The thickness of the TSPO/SDS layer es-
timated from QCM-D data was approximately 57 Å (Section 3.5);
however, this estimate from the QCM-D frequency signal also includes
coupled SDS and solvent. The low resolution structure of the TspO, the
TSPO homologue from R. sphaeroides, indicates that the length of a
TspO monomer in the membrane is approximately 40 Å [65]. This
length represents the transmembrane helix segments of the protein,
and does not take into account extramembrane regions [65]. Consider-
ing that the TSPO is predicated to span the thickness of the membrane
and have short extramembrane loops [10], a thickness of 51 Å for the
immobilised TSPO layer is reasonable (Fig. 8).
The surface coverage estimated from reﬂectivity data was 23%;
lower than the 50% coverage estimated by QCM-D (Section 3.5). How-
ever, the coverage of protein only is difﬁcult to extract from QCM-D
data because of the contribution of SDS, lipid and coupled solvent to
the signal. The protein coverage here is slightly lower, but comparable
to that reported for the membrane protein OmpF immobilised to gold
via thiol bonds [24]. The volume fraction of the TSPO layer was calculat-
ed using the SLD for the protein only, and did not explicitly take into ac-
count any contribution from the SDS. However, we observed that the
SLD of the bulk solvent was slightly altered when SDS was present, so
the presence of SDS was taken into account as a contribution to the sol-
vent surrounding the TSPO.
Finally, we attempted to reconstitute a lipid bilayer around the
immobilised TSPO layer in order to further characterise ligand interac-
tions of the TSPO in a lipid bilayer. Unlike QCM-D, the success of
TSPO/lipid bilayer reconstitutionwas limited using neutron reﬂectome-
try. Results indicate that after incubating with lipid and washing there
was very little TSPO remaining on the substrate surface.Wehypothesise
that the immobilised TSPO layer may not have been stable enough to
maintain surface coverage over the large surface area (50 cm2 com-
pared to the 1 cm2 surface of a QCM-D crystal) and repeated rinsing
necessary for neutron reﬂectometry experiments. A repeat experiment
conﬁrmed the successful formation of the DTSP-ANTA-Cu2+ modiﬁca-
tion and TSPO/SDS layer, but not lipid reconstitution, as before.
This particularHis-tag protein immobilisationmethod has not previ-
ously been used for neutron reﬂectivity measurements, and our resultsTable 5
QCM-Dmeasurements of the interaction of PK11195 with TSPO/lipid bilayers. Changes in
frequency, dissipation and Sauerbrey mass after exposure of the bare Au-DTSP-ANTA-
Cu2+ surface, DMPC/DMPE (9:1) bilayer formed on SiO2, and TSPO/DMPC/DMPE (9:1)
to PK11195. Values given are means ± SD of at least 3 independent measurements.
Composition Δ Frequency (Hz) Δ Dissipation (10−6) ΔMass (ng/cm2)
Bare Au-DTSP-ANTA-
Cu2+
0.2 ± 0.2 0.1 ± 0.1 –
DMPC/DMPE (9:1) −1.5 ± 0.1 0.9 ± 0.1 26 ± 2
TSPO/DMPC/
DMPE (9:1)
−8.6 ± 1.7 0.9 ± 0.4 146 ± 29
AB
C
Fig. 8. Neutron reﬂectivity measurements of a TSPO/SDS layer. (A) Neutron reﬂectivity
proﬁles of TSPO/SDS immobilised to a DTSP-ANTA-Cu2+ modiﬁed gold surface measured
in D2O (blue), CMAu (red), and H2O (green). Points and error bars are themeasured data,
and lines are the ﬁts to the data. (B) Corresponding scattering length density proﬁle of the
TSPO/SDS layer. (C) Schematic of detergent solubilised TSPO immobilised to a gold surface
modiﬁed with DTSP-ANTA-Cu2+ derived from reﬂectivity data (layers not to scale).
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that is comparable with other immobilisation techniques used for neu-
tron reﬂectometry [24]. It was possible to measure the thickness and
surface coverage of the immobilised TSPO layer in detergent (Fig. 8),
but the use of this method for complete TSPO/lipid bilayer formation
for neutron reﬂectometry experiments revealed problems with up-scaling and prolonged stability. Overall, however, the TSPO/lipid system
as it is seems promising for studying the interaction of TSPO with a
range of ligands with QCM-D, and with improvement of the system
for neutron reﬂectometry the effect of these interactions on protein
conformation could be studied in the future.
4. Conclusions
This work demonstrates the use of QCM-D and neutron reﬂectome-
try as part of the systematic characterisation of a ligand's interaction
with both its membrane protein target and the surroundingmembrane
environment. We found evidence that the TSPO ligand PK11195 inter-
acts with lipids, incorporating into lipid bilayer chain regions and caus-
ing a change in rigidity. This is the ﬁrst direct evidence that PK11195 is
incorporated into lipid bilayers, while it has been previously assumed
that it partitions intomembranes to a degree due to its high lipophilicity
and high levels of non-speciﬁc binding. The evidence that PK11195
changes the biophysical properties of lipid bilayers has implications
for the functional effects of PK11195 observed at high concentrations.
It is possible that some of the TSPO-independent effects of PK11195
could bemediated by PK11195 inserting into themembrane and chang-
ing its ﬂuidity to modulate the function of other proteins. A better un-
derstanding of the interaction of PK11195 with lipid membranes will
lead to a more complete picture of how this ligand exerts its TSPO-
independent effects, and how itmight inﬂuencemembrane proteins, in-
cluding TSPO, by altering the surrounding membrane environment.
In addition, we demonstrated the successful formation of a solid
supported TSPO/lipid bilayer with QCM-D, and the detection of ligand
interaction with the TSPO. Exposure of the TSPO/lipid bilayer to
PK11195 resulted in a larger than expected response, which is likely
to indicate a conformational change of the TSPO. This work demon-
strates a TSPO-lipid system that can be used for investigating the inter-
action between TSPO and other ligands and antibodies with QCM-D,
with the potential to detect conformational changes. Our neutron re-
ﬂectometrymeasurements revealed the thickness and surface coverage
of immobilised TSPO in detergent, but the system needs further devel-
opment to study a TSPO/lipid bilayer and its ligand interactions. The
eventual aim of the neutron reﬂectometry experiments was to explore
the conformational changes that were indicated in QCM-D data during
interaction with PK11195. Future experiments will aim to improve
the stability of the immobilised TSPO layer, such that lipid can be
reconstituted around it and ligand interactions can be studied.
There is increasing recognition that drug–membrane interactions
maymediate a range of drug responses, possibly by altering biophysical
properties of themembrane that affect the conformation and activity of
associatedmembrane proteins. Drug–membrane interactions thus have
wider implications for the apparent afﬁnity of drug ligands for their
receptors.
In the case of TSPO and its ligands, recent discussions have highlight-
ed variability in binding proﬁles and afﬁnities between patients, tissues,
cell types, and species [68–71]. Some of these apparent afﬁnity varia-
tions may not be solely due to sequence variations in the binding do-
main. A drug–membrane interaction, such as PK11195 with the cell
membrane,may contribute to the variable afﬁnities andbinding proﬁles
of TSPO ligands, potentially by altering the membrane environment or
conformation of the protein, causing homo- or hetero-oligomer forma-
tion, or a combination of these. Thismay, for example, cause the appear-
ance of cooperative binding. Different tissue speciﬁc afﬁnities [69] may
potentially reﬂect different molecular environments. For example, dif-
ferent lipid membrane compositions may interact differently with a li-
gand, notably if it is highly lipophilic, as is the case for most current
TSPO ligands, causing apparent differences in the afﬁnity of a ligand
for a particular protein target.
The apparent binding afﬁnity of a ligandmay thus represent an inte-
gration of receptor–ligand and membrane–ligand interactions. Hence,
both drug–receptor and drug–membrane interactions should be
1029C.R. Hatty et al. / Biochimica et Biophysica Acta 1838 (2014) 1019–1030considered for a more complete picture of the overall response to a
drug. In the case of TSPO it will help us to understand not only how li-
gands interact directly with TSPO to modulate function, but also how
its ligands, such as PK11195, interact with the membrane to modulate
the activity of both TSPO and other proteins. A deeper understanding
of dual receptor and membrane interactions of a ligand could provide
multiple strategies for therapeutic interventions.
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